Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct;4(5):e1387.
doi: 10.1002/cnr2.1387. Epub 2021 Apr 9.

Association between somatostatin analogues and diabetes mellitus in gastroenteropancreatic neuroendocrine tumor patients: A Surveillance, Epidemiology, and End Results-Medicare analysis of 5235 patients

Katherine Ni  1 , Jeong Yun Yang  1 , Kiwoon Baeg  2 , Amanda C Leiter  3 , Grace Mhango  2 , Emily J Gallagher  3   4 , Juan P Wisnivesky  5 , Michelle K Kim  2
Affiliations

Association between somatostatin analogues and diabetes mellitus in gastroenteropancreatic neuroendocrine tumor patients: A Surveillance, Epidemiology, and End Results-Medicare analysis of 5235 patients

Katherine Ni et al. Cancer Rep (Hoboken). 2021 Oct.

Abstract

Background: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are increasingly common malignancies and tend to have favorable long-term prognoses. Somatostatin analogues (SSA) are a first-line treatment for many NETs. Short-term experiments suggest an association between SSAs and hyperglycemia. However, it is unknown whether there is a relationship between SSAs and clinically significant hyperglycemia causing development of diabetes mellitus (DM), a chronic condition with significant morbidity and mortality.

Aim: In this study, we aimed to compare risk of developing DM in patients treated with SSA vs no SSA treatment.

Methods and results: Using the Surveillance, Epidemiology, and End Results (SEER) database and linked Medicare claims (1991-2016), we identified patients age 65+ with no prior DM diagnosis and a GEP-NET in the stomach, small intestine, appendix, colon, rectum, or pancreas. We used χ2 tests to compare SSA-treated and SSA-untreated patients and multivariable Cox regression to assess risk factors for developing DM. Among 8464 GEP-NET patients, 5235 patients had no prior DM and were included for analysis. Of these, 784 (15%) patients received SSAs. In multivariable analysis, the hazard ratio of developing DM with SSA treatment was 1.19, which was not statistically significant (95% CI 0.95-1.49). Significant risk factors for DM included black race, Hispanic ethnicity, prior pancreatic surgery, prior chemotherapy, tumor size >2 cm, pancreas tumors, and higher Charlson scores.

Conclusion: DM was very common in GEP-NET patients, affecting 53% of our cohort. Despite prior studies suggesting an association between SSAs and hyperglycemia, our analysis found similar risk of DM in SSA-treated and SSA-untreated GEP-NET patients. Further studies are needed to better understand this relationship. As NET patients have increasingly prolonged survival, it is crucial to identify chronic conditions such as DM that these patients may be at elevated risk for.

Keywords: SEER; cancer survivorship; digestive cancer; epidemiology; neuroendocrine tumor; somatostatin analogue.

PubMed Disclaimer

Conflict of interest statement

Author J.W. received consulting honorarium from Sanofi, Banook, and GSK, and a research grant from Sanofi. Author E.G. has an advisory role for Novartis and consulting role for Seattle Genetics. The other authors declare no potential conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Survival in GEP‐NET patients with diabetes mellitus (DM) vs no DM
See this image and copyright information in PMC

References

    1. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063‐3072. - PubMed
    1. Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335‐1342. - PMC - PubMed
    1. Kim MK, Warner RR, Roayaie S, et al. Revised staging classification improves outcome prediction for small intestinal neuroendocrine tumors. J Clin Oncol. 2013;31(30):3776‐3781. - PMC - PubMed
    1. Halperin DM, Shen C, Dasari A, et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population‐based study. Lancet Oncol. 2017;18(4):525‐534. - PMC - PubMed
    1. National Diabetes Statistics Report . Centers for Disease Control and Prevention. Translation DoD. 2020;2020:2.

Publication types

MeSH terms

Supplementary concepts